Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(12), P. 1641 - 1641
Published: Dec. 6, 2024
Molecular
imaging
is
a
growing
field,
driven
by
technological
advances,
such
as
the
improvement
of
PET-CT
scanners
through
introduction
digital
detectors
and
with
an
extended
field
view,
resulting
in
much
higher
sensitivity
variety
new
specific
radiopharmaceuticals
that
allow
visualization
molecular
pathways
even
theragnostic
approaches.
In
oncology,
development
dedicated
tracers
crucial
for
personalized
therapeutic
Novel
peptides
many
different
targets,
PD-1
PD-L1
expression,
chemokine
HER
T-cell
imaging,
microenvironmental
FAP
more.
this
article,
we
review
recent
advances
non-[18F]FDG
PET
their
current
clinical
applications
well
some
future
aspects.
Cancer Imaging,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: Jan. 27, 2025
Abstract
Background
Programmed
cell
death
1/programmed
ligand-1
(PD-L1)-based
immune
checkpoint
blockade
is
an
effective
treatment
approach
for
non-small-cell
lung
cancer
(NSCLC).
However,
immunohistochemistry
does
not
accurately
or
dynamically
reflect
PD-L1
expression
owing
to
its
spatiotemporal
heterogeneity.
Herein,
we
assessed
the
feasibility
of
using
a
68
Ga-labeled
anti-PD-L1
nanobody,
Ga-NODAGA-NM-01,
PET
imaging
PD-L1.
Methods
Micro-PET/CT
and
biodistribution
studies
were
performed
on
PD-L1-positive
-negative
tumor-bearing
mice.
Additionally,
preliminary
clinical
study
was
two
patients
with
NSCLC.
NM-01
radiolabeled
Ga
without
further
purification
under
mild
conditions.
Results
Ga-NODAGA-NM-01
exhibited
radiochemical
purity
(>
98%),
high
stability
in
vitro
,
rapid
blood
clearance
vivo
.
Specific
accumulation
observed
mice,
good
tumor-to-background
ratio
0.5h
post-injection.
Furthermore,
PET/CT
found
be
safe
no
adverse
events
distinct
uptake
primary
metastatic
lesions
patient,
higher
maximal
standardized
value
than
that
PD-L1-negative
patient
1h
Conclusions
can
prepared
simple
method
conditions
lesions.
our
findings
need
confirmed
large
cohort.
Trial
registration
NCT02978196.
Registered
February
15,
2018.
Journal of Nuclear Medicine,
Journal Year:
2024,
Volume and Issue:
unknown, P. jnumed.124.268509 - jnumed.124.268509
Published: Nov. 7, 2024
The
diagnosis
and
surveillance
of
clear
cell
renal
carcinoma
(ccRCC)
remains
a
clinical
challenge.
high
specific
expression
the
cluster
differentiation
70
(CD70)
in
ccRCC
makes
it
potential
diagnostic
therapeutic
target.
Molecular
imaging
plays
a
vital
role
in
diagnosing
diseases,
monitoring
treatments,
and
evaluating
therapeutic
efficacy
by
enabling
noninvasive
visualization
of
biological
processes.
Nanobodies,
single-domain
antibodies
derived
from
camelids,
have
emerged
as
promising
candidates
for
wide
range
biomedical
applications
due
to
their
unique
properties,
including
small
size,
high
affinity,
rapid
clearance,
deep-tissue
penetration.
While
effective
radiolabeling
techniques
remain
major
challenge
fully
realize
clinical
potential,
this
review
aims
present
recent
advances
nanobody
radiolabeling,
focusing
on
radionuclides
like
64Cu,
68Ga,
89Zr,
111In,
along
with
associated
chelators
conjugation
methods.
We
highlight
the
development
innovative
chelators,
p-SCN-Bn-HOPO
desferrioxamine
derivatives
that
enhance
specificity
stability,
well
influence
biodistribution
pharmacokinetics.
These
findings
essential
nanobody-based
molecular
precise
diagnostics
targeted
therapy.
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 10, 2025
Galectins
play
significant
roles
in
regulating
immune
responses,
posing
challenges
for
cancer
immunotherapy.
The
development
of
galectin
inhibitors
has
been
limited
by
their
high
structural
homology
and
the
lack
noninvasive
imaging
tools
to
identify
potential
responsive
patients.
We
developed
12
galectin-7-specific
using
nanobodies
(Nbs)
identified
G7N8
as
lead
Nb.
was
conjugated
with
NOTA
chelator,
labeled
copper-64
([64Cu]Cu),
used
a
radiotracer
PET
triple-negative
breast
(TNBC)
mouse
model.
Nbs
demonstrated
affinity
galectin-7,
no
binding
activity
other
galectins
tested.
inhibited
galectin-7
T-cell
glycoreceptors
reduced
subsequent
apoptosis.
[64Cu]Cu-NOTA-G7N8
showed
selective
accumulation
at
20
h
(P
=
0.001).
that
inhibit
apoptosis
enable
TNBC,
providing
novel
investigating
regulation
enhancing
Immunotherapy Advances,
Journal Year:
2024,
Volume and Issue:
4(1)
Published: Jan. 1, 2024
The
evolving
landscape
of
cancer
immunotherapy
has
revolutionized
treatment.
However,
the
dynamic
tumor
microenvironment
led
to
variable
clinical
outcomes,
indicating
a
need
for
predictive
biomarkers.
Noninvasive
nuclear
imaging,
using
radiolabeled
modalities,
aided
in
patient
selection
and
monitoring
their
treatment
response.
This
approach
holds
promise
improving
diagnostic
accuracy,
providing
more
personalized
regimen,
enhancing
Nanobodies
or
single-domain
antibodies,
derived
from
camelid
heavy-chain
allow
early
timepoint
detection
targets
with
high
target-to-background
ratios.
To
date,
plethora
nanobodies
have
been
developed
imaging
tumor-specific
antigens,
immune
checkpoints,
cells,
both
at
preclinical
level.
review
comprehensively
outlines
recent
advancements
nanobody-based
on
levels.
Additionally,
impact
expected
future
use
radiopharmaceuticals
supporting
diagnosis
follow-up
are
discussed.
